959.60 -8.85 (-0.91%)
2.7M NSE+BSE Volume
NSE May 30, 2023 03:31 PM
Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
---|---|---|---|---|---|---|---|---|---|---|---|
27 May 2023 | Sun Pharmaceutical I.. |
Motilal Oswal
|
959.60 | 1160.00 | 969.90 (-1.06%) | 20.88 |
Buy
|
||||
27 May 2023 | Sun Pharmaceutical I.. |
ICICI Securities Limited
|
959.60 | 1160.00 | 969.90 (-1.06%) | 20.88 |
Buy
|
Specialty portfolio is amplifying margins
ICICI Securities Limited
Sun Pharmaceutical’s (Sun) Q4FY23 performance was decent, aided by traction in specialty portfolio, India branded and launch of Revlimid in the US. Specialty business sales contribution had increased to 16.6% in FY23 (14% in FY22) and key assets like Ilumya, Winlevi and Cequa will likely improve the share to 21% by FY25E.
|
|||
27 May 2023 | Sun Pharmaceutical I.. |
ICICI Direct
|
959.60 | 1140.00 | 969.90 (-1.06%) | 18.80 |
Buy
|
||||
01 Feb 2023 | Sun Pharmaceutical I.. |
ICICI Securities Limited
|
959.60 | 1001.00 | 1034.50 (-7.24%) | Target met |
Hold
|
In-line performance; valuations fair
ICICI Securities Limited
Sun Pharmaceutical’s (Sun) Q3FY23 performance was largely in line with our estimates. Consolidated revenue grew 12.9% YoY to Rs111.4bn (I-Sec: Rs110.5bn) driven by US and emerging market sales. EBITDA margin stood at 26.0% (I-Sec: 26.6%). Specialty portfolio grew 10.7% QoQ to US$223mn (ex- milestone income) led by growth in Ilumya and Winlevi.
|
|||
01 Feb 2023 | Sun Pharmaceutical I.. |
ICICI Direct
|
959.60 | 1210.00 | 1014.90 (-5.45%) | 26.09 |
Buy
|
||||
31 Jan 2023 | Sun Pharmaceutical I.. |
Motilal Oswal
|
959.60 | 1220.00 | 1034.50 (-7.24%) | 27.14 |
Buy
|
||||
19 Jan 2023 | Sun Pharmaceutical I.. |
Motilal Oswal
|
959.60 | 1200.00 | 1040.55 (-7.78%) | 25.05 |
Buy
|
||||
10 Nov 2022 | Sun Pharmaceutical I.. |
Geojit BNP Paribas
|
959.60 | 1078.00 | 1013.55 (-5.32%) | 12.34 |
Hold
|
||||
03 Nov 2022 | Sun Pharmaceutical I.. |
SMC online
|
959.60 | 1039.90 (-7.72%) |
Results Update
|
||||||
03 Nov 2022 | Sun Pharmaceutical I.. |
KRChoksey
|
959.60 | 1229.00 | 1051.95 (-8.78%) | 28.07 |
Buy
|
||||
02 Nov 2022 | Sun Pharmaceutical I.. |
Motilal Oswal
|
959.60 | 1240.00 | 1051.95 (-8.78%) | 29.22 |
Buy
|
||||
02 Nov 2022 | Sun Pharmaceutical I.. |
Prabhudas Lilladhar
|
959.60 | 1175.00 | 1044.20 (-8.10%) | 22.45 |
Buy
|
||||
02 Nov 2022 | Sun Pharmaceutical I.. |
ICICI Securities Limited
|
959.60 | 1002.00 | 1036.60 (-7.43%) | Target met |
Hold
|
||||
02 Nov 2022 | Sun Pharmaceutical I.. |
ICICI Direct
|
959.60 | 1225.00 | 1051.95 (-8.78%) | 27.66 |
Buy
|
||||
01 Nov 2022 | Sun Pharmaceutical I.. |
Bonanza
|
959.60 | 1072.00 | 1036.60 (-7.43%) | Target met |
Buy
|
||||
01 Nov 2022 | Sun Pharmaceutical I.. |
BOB Capital Markets Ltd.
|
959.60 | 1100.00 | 1051.95 (-8.78%) | 14.63 |
Hold
|
||||
03 Oct 2022 | Sun Pharmaceutical I.. |
KRChoksey
|
959.60 | 1114.00 | 948.65 (1.15%) | 16.09 |
Buy
|
||||
05 Aug 2022 | Sun Pharmaceutical I.. |
Edelweiss
|
959.60 | 916.00 | 915.95 (4.77%) | Target met |
Buy
|
||||
01 Aug 2022 | Sun Pharmaceutical I.. |
SMC online
|
959.60 | 897.00 (6.98%) |
Results Update
|
||||||
31 Jul 2022 | Sun Pharmaceutical I.. |
Prabhudas Lilladhar
|
959.60 | 1070.00 | 918.70 (4.45%) | Target met |
Buy
|
||||
more
loading
|